Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-0009PMID 17545523
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles

  2006cited by this paper
• Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment

  2006cited by this paper
• Chemotherapeutic approaches for targeting cell death pathways.

  2006cited by this paper
• Cytokeratin profile in mucoepidermoid carcinoma is not related to its histological grading of malignancy.

  2006cited by this paper
• Necrotic death as a cell fate.

  2006cited by this paper
• Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma.

  2006cited by this paper
• Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study

  2006cited by this paper
• Mitotic Catastrophe Results in Cell Death by Caspase-Dependentand Caspase-Independent Mechanisms

  2006cited by this paper
• Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

  2006cited by this paper
• Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

  2006cited by this paper
• Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis

  2005cited by this paper
• Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells

  2005cited by this paper
• Repopulation of cancer cells during therapy: an important cause of treatment failure

  2005cited by this paper
• Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.

  2005cited by this paper
• Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

  2005cited by this paper
• Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

  2005cited by this paper
• Apoptotic pathways and therapy resistance in human malignancies.

  2005cited by this paper
• The role of apoptosis in cancer development and treatment response

  2005cited by this paper
• Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

  2005cited by this paper
• Validation of the English and Chinese versions of the Quick-FLIC quality of life questionnaire

  2005cited by this paper
• Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.

  2004cited by this paper
• Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

  2004cited by this paper
• Alkylating DNA damage stimulates a regulated form of necrotic cell death.

  2004cited by this paper
• Comparison of anthracycline-induced death of human leukemia cells: Programmed cell death versus necrosis

  2002cited by this paper
• Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin*

  2002cited by this paper
• Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.

  2002cited by this paper
• A Novel High-Through-Put Assay for Screening of Pro-Apoptotic Drugs

  2002cited by this paper
• Tumor senescence as a determinant of drug response in vivo.

  2002cited by this paper
• the Decision between Apoptosis and Necrosis Photosensitization with Zinc ( II ) Phthalocyanine as a Switch in Updated

  2001cited by this paper
• A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.

  2001cited by this paper
• Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis

  1999cited by this paper
• Apoptosis Generates Stable Fragments of Human Type I Keratins*

  1997cited by this paper
• Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis

  1997cited by this paper
• Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

  1996cited by this paper
• Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18.

  1996cited by this paper
• The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.

  1995cited by this paper
• Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance.

  1995cited by this paper
• Induction of apoptosis--new targets for cancer chemotherapy.

  1992cited by this paper
• Translational Therapeutics

  year unknowncited by this paper

• Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications

  2025cites this paper
• Development of point-of-care tests for urinary bladder cancer - an historic review and view to future prospectives.

  2025cites this paper
• Beclin-1: a therapeutic target at the intersection of autophagy, immunotherapy, and cancer treatment

  2024cites this paper
• Dysregulation of autophagy in gastric carcinoma: Pathways to tumor progression and resistance to therapy.

  2024cites this paper
• Cell based and In vivo systematic evaluation of some Egyptian plant extracts targeting breast cancer.

  2024cites this paper
• Deciphering the Functional Status of Breast Cancers through the Analysis of Their Extracellular Vesicles

  2023cites this paper
• Can M-30, M-65, and IL-6 serum levels be useful markers in the diagnosis of preeclampsia and gestational diabetes?

  2023cites this paper
• Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study

  2023cites this paper
• “In the light of evolution:” keratins as exceptional tumor biomarkers

  2023cites this paper
• Higher Levels of Plasma Fetuin-A, Nrf2, and Cytokeratin 18 in Patients with Hashimoto’s Disease

  2023cites this paper
• Cyclic Dodecapeptide Induces Cell Death Through Membrane–Peptide Interactions in Breast Cancer Cells

  2022cites this paper
• Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer

  2022cites this paper
• Diagnostic and Prognostic Value of M 30 and M 65 in Laryngeal Squamous Cell Carcinoma

  2021cites this paper
• MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection

  2021cites this paper
• Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study

  2021cites this paper
• Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

  2021cites this paper
• In vitro and in vivo evaluation of paclitaxel-induced release of apoptotic biomarker ccCK18 to guide treatment optimization in ovarian cancer

  2021cites this paper
• Development of a highly sensitive chemiluminescent enzyme immunoassay for fragmented cytokeratin 18 using new antibodies

  2021cites this paper
• Serum Cytokeratin 18 as a Metastatic and Therapeutic Marker for Extramammary Paget’s Disease

  2021cites this paper
• Necrosis Rather Than Apoptosis is The Dominant form of Alveolar Epithelial Cell Death In Lipopolysaccharide-Induced Experimental Acute Respiratory Distress Syndrome Model.

  2020cites this paper
• In vitro and in vivo evaluation of paclitaxel-induced release of apoptotic biomarker ccCK18 to guide treatment optimization in ovarian cancer 

  2020cites this paper
• Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel.

  2020cites this paper
• Generation of Rat Monoclonal Antibody for Cytokeratin 18 by Immunization of Three-Dimensional-Cultured Cancer Cells

  2020cites this paper
• Autophagy alleviates amiodarone-induced hepatotoxicity

  2020cites this paper
• OXIDATIVE STRESS, DNA DAMAGE AND APOPTOSIS LEVELS IN THOSE WHO USE BORDERLINE HIGH LEVEL FLUORIDE CONTENT DRINKING WATER

  2020cites this paper
• Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study

  2020influential citation
• Targeting apoptosis in cancer therapy

  2020cites this paper
• Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.

  2020cites this paper
• Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

  2019cites this paper
• Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

  2019cites this paper
• Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis

  2018cites this paper
• Why is Immunohistochemical Detection of Metastasized Breast Cancer Cells in the Immunocompetent Host Not Always Easy?

  2018cites this paper
• Caspase-Cleaved Cytokeratin 18 as a Potential Molecular Biomarker for Monitoring Chemotherapeutic Response in Breast Cancer Patients

  2018cites this paper
• Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer

  2018cites this paper
• The efficacy of serum cell death biomarkers for diagnosing biliary tract cancer

  2018cites this paper
• Letter: reduction in chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low‐risk patients – more questions than answers

  2017cites this paper
• Proteomic Profiling Reveals the Induction of UPR in Addition to DNA Damage Response in HeLa Cells Treated With the Thiazolo[5,4‐b]Quinoline Derivative D3ClP

  2017cites this paper
• Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment

  2017cites this paper
• Mechanisms of AEG-1 and CXCR4 gene expression regulating the epithelial-mesenchymal transition pathway involved in brain metastases of breast cancer.

  2017cites this paper
• Letter: cytokeratin‐18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors’ reply

  2017cites this paper
• Serum cytokeratin-18 is a non-invasive biomarker for evaluating disease severity in patients with liver cirrhosis and hepatocellular carcinoma

  2017cites this paper
• PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER.

  2017cites this paper
• Effect of Helix aspersa extract on TNFα, NF-κB and some tumor suppressor genes in breast cancer cell line Hs578T

  2017cites this paper
• An Approach to Improve the Detection System of a Diagnostic Enzyme-Linked Immunosorbent Assay

  2017cites this paper
• Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model

  2017cites this paper
• Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis

  2016influential citation
• Circulating Cell Death Biomarkers May Predict Survival in Human Lung Transplantation.

  2016cites this paper
• Expression of Cytokeratin - 18 in Serum as a Biomarker of Apoptosis & Necrosis in Carcinoma Breast

  2016cites this paper
• AGS 16 F Is a Novel Antibody Drug Conjugate Directed against ENPP 3 for the Treatment of Renal Cell Carcinoma

  2016cites this paper
• Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression

  2016cites this paper
• Monitoring the response of head and neck tumour tissue to irradiation using a microfluidic-based approach

  2016cites this paper
• Serum Cell Death Biomarker Mirrors Liver Cancer Regression after Transarterial Chemoembolisation

  2016cites this paper
• Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

  2016cites this paper
• Expression of Steroid Receptors and Cytokeratin 18 in Breast Cancer after Neoadjuvant Chemotherapy

  2015cites this paper
• Cytokeratin 18 for chemotherapy efficacy in gastric cancer

  2015cites this paper
• Analysis of 32 Blood-Based Protein Biomarkers for their Potential to Diagnose Colorectal Cancer

  2015cites this paper
• A Small Molecule with Anticancer and Antimetastatic Activities Induces Rapid Mitochondrial-Associated Necrosis in Breast Cancer

  2015cites this paper
• A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer

  2015cites this paper
• Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts

  2015cites this paper
• The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.

  2015cites this paper
• AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma

  2015cites this paper
• Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC

  2015cites this paper
• Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma

  2015cites this paper
• The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18

  2015cites this paper
• Quantitative interactome analysis reveals a chemoresistant edgotype

  2015cites this paper
• Effets de la chirurgie bariatrique sur les complications hépatiques de l’obésité

  2014cites this paper
• Anticancer Bioactive Peptide‐3 Inhibits Human Gastric Cancer Growth by Suppressing Gastric Cancer Stem Cells

  2014cites this paper
• Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients

  2014cites this paper
• Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

  2014cites this paper
• Consequences of activating the calcium-permeable ion channel TRPV1 in breast cancer cells with regulated TRPV1 expression.

  2014cites this paper
• Clinical significance of serum M30 and M65 levels in patients with breast cancer.

  2014cites this paper
• M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease

  2014influential citation
• Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling

  2014cites this paper
• Serum CK 18 as a Predictive Factor of Response to Chemotherapy in Locally Advanced and Metastatic Breast Cancer

  2014cites this paper
• Serum Caspase-3 and Caspase-7 as Predictive Factors of Response in Locally Advanced and Metastatic Breast Carcinoma

  2014cites this paper
• Serum CK18 as a Predictive Factor of Response to Chemotherapy in Locally Advanced and Metastatic Breast Cancer

  2014cites this paper
• Towards model-based dose optimization of antibiotic and anti-cancer treatment regimens in specific patient populations

  2014cites this paper
• Rôle de l'ostéopontine dans les complications hépatiques induites par l'alcool, l'obésité et l'ischémie-reperfusion

  2014cites this paper
• Early Biomarkers in Breast Cancer

  2014cites this paper
• Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients

  2013cites this paper
• A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

  2013cites this paper
• A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

  2013cites this paper
• Clinical significance of serum M30 and M65 levels in melanoma

  2013cites this paper
• Serum cytokeratin 18 as a biomarker for gastric cancer

  2013cites this paper
• The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer

  2013cites this paper
• The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy

  2013cites this paper
• Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

  2013cites this paper
• Genomic and proteomic biomarkers in the drug R&D process

  2013cites this paper
• Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel–Carboplatin Chemotherapy? A Retrospective Study

  2012cites this paper
• Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy

  2012cites this paper
• Biological Functions of Cytokeratin 18 in Cancer

  2012cites this paper
• Biomarkers of cell death applicable to early clinical trials.

  2012cites this paper
• The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer

  2012cites this paper
• Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

  2012influential citation
• Cytokeratins - Tools in Oncology

  2012cites this paper
• Biological efects of South African plant extracts on RBBp6 as anti-cancer therapy in lung cancer

  2012cites this paper
• Bromelain-Induced Apoptosis in GI-101A Breast Cancer Cells

  2012cites this paper
• Combining [11C]-AnxA5 PET Imaging with Serum Biomarkers for Improved Detection in Live Mice of Modest Cell Death in Human Solid Tumor Xenografts

  2012cites this paper
• Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL.

  2012cites this paper
• Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

  2012cites this paper